Global Health Ventures Inc.
OTC Bulletin Board : GHLV

Global Health Ventures Inc.

September 20, 2010 09:25 ET

Global Health Ventures to Develop Sublingual Telcagepant for Migraine

VANCOUVER, BRITISH COLUMBIA--(Marketwire - Sept. 20, 2010) - Global Health Ventures Inc. (OTCBB:GHLV) (the "Company"), a Specialty Pharma with focus on sublingual drug delivery, is pleased to announce that, it has initiated the development of a sublingual formulation of Telcagepant. Telcagepant is believed to be a powerful anti-migraine drug developed by Merck & Company. The drug blocks the recently discovered clacitonin-gene related hormone receptor (CGRP), a powerful vasodilator protein believed to be a key player in migraine. Merck initiated the development of Telcagepant in 2007 and spent millions of dollar on the product. Unfortunately the drug failed to obtain FDA approval, due to side effects associated with the drug's liver metabolism.

Studies showed patients taking Telcagepant experienced high levels of liver enzymes that was responsible for side effects such as nasopharyngitis, nausea, vomiting, dizziness, abnormal skin sensation, chest and abdominal pain.

It is scientifically proven that the sublingual route of drug delivery, drug bypasses liver as first passage into the body. Drugs administered via sublingual route enter blood first and reaches the site of action before entering the liver. Therefore, the drug will have far less side effects. Therefore, lower dosage of the drug can be used which provides similar efficacy as high dosage given orally. It is therefore highly logical to develop a sublingual formulation of the drug and attempt to capture this lucrative migraine market.

Migraine is a neurological disease affecting 10-15% of the population, primarily women aged 25-55. According to the National Headache Foundation, there are 28 million patients in the United States or 303 million people worldwide who suffer from migraine headaches. In 2008, the migraine market was valued at $4.6 billion and it is currently growing at an unprecedented rate due to socioeconomic conditions.

"We are pleased to have a technology that applies to a vast majority of drugs to be delivered differently from their current way of delivery. Sublingual route of drug administration is a wonderful tool for the drugs that otherwise have limited benefit by oral route. Sublingual route helps the drug to reach the blood stream rapidly without major side effects associated with liver drug's breakdown. Further, it helps the drug to reach its site of action by bypassing gastrointestinal breakdown and overall the drug initiates its action much rapidly due to the direct entry into blood," said Dr. Hassan Salari, Global Health President & CEO.

About Global Health Ventures

Global Health Ventures is a specialty pharmaceutical company with expertise in drug delivery and formulation. The Company has currently a proprietary platform technology for drug delivery via the sublingual (under the tongue) route. This unique method delivers drugs to the bloodstream quickly with minimal drug breakdown in the liver or gastrointestinal system, a process that can greatly reduce side effects associated with the drugs. The Company's lead therapeutic product is a male sexual enhancement drug that is delivered via sublingual route and is called X-Excite. In experimental studies, X-Excite has been shown to reach the blood stream rapidly, producing maximal effect and having less of the unwanted side effects associated with oral delivery route. X-Excite is presently in clinical development in Europe. The second drug of ours "B-Relax" is also under development in Canada for anxiety. The third drug to be developed is the anti-migraine drug using the same technology as the two previous ones. The Company plans to use the same technology to deliver a vast number of other FDA approved and non approved drugs that require faster delivery, or reduced hepatic and gastrointestinal side effects. These include stress relief, sleeping disorders, pain killers, anti-allergy medications, energy boosters and addiction replacement therapies.

Notice Regarding Forward Looking Statements - This press release includes forward-looking statements that involve a number of risks and uncertainties, including the success of the products in commercializing and developing. Further, the risks involve the ability of the Company to raise capital to fund its operations and the capital requirements for the development and marketing of its products. Investors are encouraged to review the risk factors listed or described from time to time in the Company's filings (10K) with the Securities and Exchange Commission.

Contact Information